These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Whaley-Connell A; Johnson MS; Sowers JR Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958 [TBL] [Abstract][Full Text] [Related]
4. Aldosterone receptor antagonists: current perspectives and therapies. Guichard JL; Clark D; Calhoun DA; Ahmed MI Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977 [TBL] [Abstract][Full Text] [Related]
5. Aldosterone and the risk of hypertension. Xanthakis V; Vasan RS Curr Hypertens Rep; 2013 Apr; 15(2):102-7. PubMed ID: 23378101 [TBL] [Abstract][Full Text] [Related]
6. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Valaiyapathi B; Calhoun DA Curr Hypertens Rep; 2018 Mar; 20(3):23. PubMed ID: 29556729 [TBL] [Abstract][Full Text] [Related]
7. [Primary hyperaldosteronism: should we pose its systematic detection at health centres?]. Maciá-Bobes C; Ronzón-Fernández A; Castaño-Fernández G; Botas-Cervero P Aten Primaria; 2006 Feb; 37(2):104-7. PubMed ID: 16527118 [No Abstract] [Full Text] [Related]
10. The role of aldosterone antagonists in the management of resistant hypertension. Nishizaka MK; Calhoun DA Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075 [TBL] [Abstract][Full Text] [Related]
11. [Conn syndrome as cause of stubborn hypertension. Which hypertensives should you screen?]. Reincke M MMW Fortschr Med; 2003 Feb; 145(9):37-40. PubMed ID: 12666528 [No Abstract] [Full Text] [Related]
14. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism. Chrissobolis S Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785 [TBL] [Abstract][Full Text] [Related]
15. [Therapy-resistant hypertension--the value of aldosterone antagonists]. Quack I; Reincke M; Rump LC MMW Fortschr Med; 2007 Nov; 149(46):39-40. PubMed ID: 18069192 [TBL] [Abstract][Full Text] [Related]
16. Primary Hyperaldosteronism: Approach to Diagnosis and Management. El-Asmar N; Rajpal A; Arafah BM Med Clin North Am; 2021 Nov; 105(6):1065-1080. PubMed ID: 34688415 [TBL] [Abstract][Full Text] [Related]
17. Reviving the use of aldosterone inhibitors in treating hypertension in obesity. Huby AC; Belin De Chantemèle EJ Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057 [TBL] [Abstract][Full Text] [Related]
18. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Epstein M; Calhoun DA Curr Hypertens Rep; 2007 Apr; 9(2):98-105. PubMed ID: 17442219 [TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases]. Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213 [TBL] [Abstract][Full Text] [Related]
20. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Funder JW Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]